About Nuvectra Corp (NVTR)
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NVTR
- CUSIP: N/A
- Previous Close: $6.15
- 50 Day Moving Average: $7.10
- 200 Day Moving Average: $6.28
- 52-Week Range: $10,337,000.00 - $4.17
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.16
- P/E Growth: 0.00
- Market Cap: $66.47M
- Outstanding Shares: 10,337,000
- Net Margins: -320.73%
- Return on Equity: -33.89%
- Return on Assets: -28.02%
- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 7.33%
- Quick Ratio: 7.33%
Companies Related to Nuvectra Corp:
Earnings History for Nuvectra Corp (NASDAQ:NVTR)Earnings History by Quarter for Nuvectra Corp (NASDAQ:NVTR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2017|| || || || || || || || |
|3/7/2017||Q4 2016||($0.89)||($1.27)||$3.97 million||$4.20 million||View||Listen|
|11/9/2016||Q3 2016||($0.88)||($0.92)||$2.81 million||$3.80 million||View||Listen|
|8/10/2016||Q216||($1.13)||($0.85)||$2.40 million||$2.50 million||View||Listen|
Earnings Estimates for Nuvectra Corp (NASDAQ:NVTR)
Current Year EPS Consensus Estimate: $-4.36 EPS
Next Year EPS Consensus Estimate: $-2.97 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Nuvectra Corp (NASDAQ:NVTR)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Nuvectra Corp (NASDAQ:NVTR)
Latest Headlines for Nuvectra Corp (NASDAQ:NVTR)
|Zacks: Analysts Set $12.00 Price Target for Nuvectra Corp (NVTR)|
www.americanbankingnews.com - March 22 at 10:31 AM
|Nuvectra Corp (NVTR) Director Acquires $152,750.00 in Stock|
www.americanbankingnews.com - March 20 at 7:55 PM
|NUVECTRA CORP Financials|
finance.yahoo.com - March 15 at 7:07 PM
|NUVECTRA CORP Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 9 at 6:46 PM
|Nuvectra Corporation (NVTR) Presents At Cowen and Company 37th Annual Health Care Conference|
seekingalpha.com - March 8 at 7:42 PM
|Q4 2016 Nuvectra Corp Earnings Release - Before Market Open|
us.rd.yahoo.com - March 7 at 11:47 PM
|Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results|
www.nasdaq.com - March 7 at 10:02 AM
|Nuvectra Corporation misses by $0.38, beats on revenue|
seekingalpha.com - March 7 at 10:02 AM
|NUVECTRA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - March 7 at 10:02 AM
|Nuvectra to Present at the 29th Annual ROTH Conference|
finance.yahoo.com - March 6 at 8:04 AM
|Nuvectra to Present at the Cowen and Company 37th Annual Health Care Conference|
finance.yahoo.com - March 1 at 10:30 AM
|Nuvectra to Report Fourth Quarter 2016 Financial Results on March 7, 2017|
finance.yahoo.com - February 21 at 5:56 PM
|Nuvectra Extends Timeline of Existing Credit Facility|
us.rd.yahoo.com - February 14 at 10:12 PM
|Nuvectra to Present at the Leerink Partners 6th Annual Global Healthcare Conference|
finance.yahoo.com - February 6 at 9:26 AM
|Nuvectra Files Regulatory Submissions for FDA and CE Mark Approvals of the Virtis™ Sacral Nerve Stimulation (SNS) System|
us.rd.yahoo.com - February 1 at 8:04 PM
|10:01 am Nuvectra files regulatory submissions with the FDA and CE Mark authorities for Virtis|
us.rd.yahoo.com - February 1 at 8:04 PM
|NUVECTRA CORP Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - January 17 at 7:18 PM
|Nuvectra Receives Frost & Sullivan’s New Product Innovation Award for Its Algovita® SCS System|
finance.yahoo.com - January 17 at 11:25 AM
|Nuvectra Corporation Signs Direct Supply Agreement|
finance.yahoo.com - December 12 at 9:57 AM
|8:01 am Nuvectra completes a direct supply agreement with Minnetronix; will begin purchasing the external peripheral devices for its Algovita spinal cord stimulation system directly from Minnetronix in the first half of 2017 as it transitio|
finance.yahoo.com - December 12 at 9:57 AM
|Nuvectra to Present at the 28th Annual Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 21 at 11:52 AM
|Nuvectra Corporation misses by $0.04, beats on revenue|
seekingalpha.com - November 10 at 9:37 AM
|Q3 2016 Nuvectra Corp Earnings Release - After Market Close|
biz.yahoo.com - November 9 at 9:03 AM
|Nuvectra to Report Third Quarter 2016 Financial Results on November 9, 2016|
finance.yahoo.com - November 2 at 6:50 PM
|Nuvectra: Post Spin-Off|
seekingalpha.com - October 5 at 11:45 AM
|Aptevo Therapeutics: A Biotech Spinoff With Potential|
seekingalpha.com - September 22 at 11:19 AM
|Edited Transcript of NVTR earnings conference call or presentation 10-Aug-16 8:30pm GMT|
finance.yahoo.com - August 18 at 6:43 PM
|Piper Jaffray Cuts Price Target on Nuvectra Corporation (NVTR) Following 2Q Revenue Beat|
www.streetinsider.com - August 12 at 9:45 AM
|Q2 2016 Nuvectra Corp Earnings Release - After Market Close|
biz.yahoo.com - August 10 at 9:40 AM
|Medical Products' Earnings on Aug 10: PRGO, NVTR & BSGM|
finance.yahoo.com - August 9 at 9:45 AM
|Nuvectra Announces Formation of Medical Advisory Board|
finance.yahoo.com - August 8 at 11:15 AM
|NUVECTRA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - August 1 at 6:19 PM
|Nuvectra to Report Second Quarter 2016 Financial Results on August 10, 2016|
finance.yahoo.com - July 27 at 4:01 PM
|Nuvectra Added to the Russell Microcap® Index|
finance.yahoo.com - June 28 at 9:00 AM
|NUVECTRA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - June 17 at 4:32 PM
|Coverage initiated on Nuvectra by Sterne Agee CRT|
finance.yahoo.com - June 3 at 7:12 AM
|Nuvectra Corp Earnings Call scheduled for 4:30 pm ET today|
biz.yahoo.com - May 11 at 4:30 PM
Frequently Asked Questions for Nuvectra Corp (NASDAQ:NVTR)
What is Nuvectra Corp's stock symbol?
Nuvectra Corp trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra Corp's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) posted its quarterly earnings data on Tuesday, March, 7th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.38. The company earned $4.20 million during the quarter, compared to analyst estimates of $3.97 million. Nuvectra Corp had a negative return on equity of 33.89% and a negative net margin of 320.73%. The business's revenue for the quarter was up 223.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.55) EPS.
When will Nuvectra Corp make its next earnings announcement?
Nuvectra Corp is scheduled to release their next quarterly earnings announcement on Tuesday, May, 9th 2017.
Where is Nuvectra Corp's stock going? Where will Nuvectra Corp's stock price be in 2017?
3 brokerages have issued 12-month price targets for Nuvectra Corp's shares. Their predictions range from $10.00 to $14.00. On average, they expect Nuvectra Corp's stock price to reach $12.00 in the next twelve months.
Who owns Nuvectra Corp stock?
Nuvectra Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.81%), Bain Capital Investors LLC (3.18%), Numeric Investors LLC (2.41%), Tudor Investment Corp Et Al (1.94%), Hodges Capital Management Inc. (1.73%) and J. Goldman & Co LP (1.61%). Company insiders that own Nuvectra Corp stock include David D Johnson, Joseph A Miller, Scott F Drees and Thomas Kelley Hickman.
Who sold Nuvectra Corp stock? Who is selling Nuvectra Corp stock?
Nuvectra Corp's stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management, Bogle Investment Management L P DE, Tudor Investment Corp Et Al, Dimensional Fund Advisors LP and Gamco Investors INC. ET AL.
Who bought Nuvectra Corp stock? Who is buying Nuvectra Corp stock?
Nuvectra Corp's stock was bought by a variety of institutional investors in the last quarter, including FNY Partners Fund LP, Hodges Capital Management Inc., Renaissance Technologies LLC and Numeric Investors LLC. Company insiders that have bought Nuvectra Corp stock in the last two years include David D Johnson, Joseph A Miller and Scott F Drees.
How do I buy Nuvectra Corp stock?
Shares of Nuvectra Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nuvectra Corp stock cost?
One share of Nuvectra Corp stock can currently be purchased for approximately $6.43.
Nuvectra Corp (NVTR) Chart for Sunday, March, 26, 2017